REMEGEN (09995) announced that on January 12, 2026, the company entered into an exclusive licensing agreement with AbbVie Group Holding Company (AbbVie) for RC148. RC148 is a novel bispecific antibody drug targeting PD-1/VEGF developed by the company. Pursuant to the agreement, AbbVie will obtain exclusive rights for the development, production, and commercialization of RC148 in regions outside Greater China. Following the effectiveness of the agreement upon receiving relevant regulatory approvals, the company will receive an upfront payment of $650 million and will be eligible for up to $4.95 billion in development, regulatory, and commercial milestone payments, in addition to tiered double-digit royalty fees based on net sales outside Greater China. The milestone payments stipulated in the agreement are contingent upon meeting certain conditions, and the final amount of milestone payments achievable by the company remains uncertain.